Reproductive activity in cows following parturition against values of certain parameters of metabolic profile

Data from literature indicate that there is a correlation between the values of reproductive parameters and the values of parameters of the metabolic profile, even though this cannot be confirmed in many cases. The objective of this work was to examine the connection between certain parameters of the metabolic profile and the restoration of reproductive activity in the postpartal period. Blood samples were taken from the cows involved in the experiment and values of parameters of the metabolic state were determined in 27 cows, of which 14 were primiparous and 13 multiparous. In the blood serum samples, we determined the concentration of glucose, total proteins, albumin, urea, and the activities of certain enzymes (alkaline phosphatase, ASAT and ALAT). It was established on the grounds of the obtained results that the delay in the establishment of reproductive activity in the postpartal period was in correlation with the blood concentrations of urea and albumin.

Generating bovine embryos through ICSI

Through ICSI, competition between sperms and also sperm-oocyte interaction are avoided thus ICSI proving reliable when sperm is not suitable for IVF. In bovine, the limiting step is represented by low rate of sperm head decondensation subsequent ICSI. Intracytoplasmatic sperm injection allows avoiding many critical moments that may occur during normal or in vitro fertilization. Oocytes were obtained from ovaries from slaughtered cows. These were transported in 0.9% NaCl solution in isothermal bags at a temperature of 25-30 ° C. The ovaries were brought from the slaughterhouse within 2 hours. Harvesting of the oocytes was made through the aspiration method. After maturation, oocytes were fertilized using sperm that was prepared using Percoll method and then treated with TritonX. The volume of the TritonX solution that accompanies the sperma and which remains in the oocyte is extremely important given that by its action, TritonX removes the acrosome, thus releasing a rich enzyme content and facilitating the dehydration of the male pronucleus. Even though the number of 2 nucleus, 2 cells or 4 cells oocytes is inferior to the data found in the literature, compared to the results achieved last year in the assisted reproduction laboratory within CLC-HC Timisoara, it marks significant progress. At the 2 cells stage, there were several oocytes from group 1 (24.39% vs. 12.5%), while at the 4 cells stage there were 14.63% oocytes from group 1 and 25% group 2. The use of TritonX solution for sperm treatment as well as shortening the duration of ICSI execution allowed us to get encouraging results. The results obtained are inferior to those presented in the literature but are far superior to those we obtained last year when the ICSI technique was assembled. Achieving the two- and four-cell embryonic stages justifies us thinking that we are mastering the ICSI technique

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Comparative relations between progesterone blood concentration and appearance of oestrus in cows

The timely detection of oestrus presents an important professional procedure with which cattle farmers, in addition to veterinarians, are very often faced, because failure to detect oestrus poses a big economic problem. The objective of this work is to evaluate the efficacy of discovering oestrus in cows by determining the progesterone concentration (P4) in blood plasma. This experiment covered 22 animals, including 15 cows and 7 heifers, in which spontaneous oestrus was discovered. P4 concentration was determined using the ELISA test in samples of blood taken from the animals at the moment of insemination. Of the 15 cows, four cows (26.6%) were not inseminated at the optimal time, and the P4 level in these animals was higher than 1 ng/ml. All the heifers showed a progesterone concentration of over 1 ng/ml, and a percentage of conception which was 85%. The high P4 level in heifers at the moment of insemination could also be a consequence of stress caused by the regrouping and separating of the animals. Even though the heifers were under stress, which is indicated by the high progesteronemia values at the moment of insemination, the percentage of conception among them was beyond expectations. Therefore, the determination of P4 values at the moment of insemination is a suitable method for improving reproduction management on cattle farms. Inappropriate treatment of cows which are expected to show oestrus can cause stress and an increase in the values of the blood concentration of P4. On the grounds of the results obtained in this work, no negative influence of stress on the insemination results in heifers was observed

Utilization of Rosmarinic and Ascorbic Acids for Maturation Culture Media in Order to Increase Sow Oocyte Quality Prior to IVF

The beneficial effect of antioxidant supplementation in maturation culture media of sow oocytes was evaluated by the expression quantification of apoptotic genes and the genes that ensure stability of germ cells during fertilization. The oocytes were cultivated for 44 h in conventional medium (C) or in medium supplemented with 105 µM rosmarinic acid (R) and 0.5 mM ascorbic acid (A) and classified into three quality classes by morphological observation from which the total RNA was isolated. The gene expression of Ptx3 and the apoptotic regulator p53, Bax and BCL-2 were evaluated by quantitative PCR technique. The decreased expression of the Bax gene in the A and R groups, compared to the control, indicates a protective role of antioxidants in the cells. Cell homeostasis was maintained, as reflected in the ratio of Bax/Bcl-2 in class I COCs (cumulus-oocyte complex) regardless of the experimental group, indicating minimum cellular stress. The expression of p53 genes was higher in all class III COC, but in A1 and R1 the expression was lower than in C1, and a similar Ptx-3 gene decreased significantly in groups A1, A2, A3 and R1 compared with control groups. Antioxidant supplementation showed beneficial effects on all morphological classes of pig COCs

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society